ADA Early Presentation Roundup: Amylin Updates Deepen Potential 1L Opportunity?

Research evidence excerpt

ADA Early Presentation Roundup: Amylin Updates Deepen Potential 1L Opportunity?

June 6, 2026 | 14:40 ET~

BioPharma

ADA Early Presentation Roundup: Amylin Updates BioPharma

Deepen Potential 1L Opportunity? Evan David Seigerman Analyst

evan.seigerman@bmo.com (212) 444-4328

Conor MacKay VP Associate

Bottom Line: conor.mackay@bmo.com (347) 988-4235

ADA Friday/Saturday Wrap-Up: We are at the ongoing American Diabetes Association Malcolm Hoffman, CFA VP Associate

(ADA) Scientific Sessions in NoLa and are on the ground highlighting our takeaways malcolm.hoffman@bmo.com (646) 438-2627

from medical review talks, and key additional data for petrelintide and zenagamtide. Legal Entity: BMO Capital Markets Corp.

Ph 2 ZUPREME-1 data for petrelintide shows strong tolerability, but less competitive

efficacy vs the ~20% weight loss demonstrated by eloralintide. With ~11% body weight

reductions at 42 weeks, petrelintide looks to be positioned more for its tolerability

profile with lower vomiting rates than placebo (3% vs. 6.2%). Results align with

physician led amylin symposium suggesting a future obesity treatment paradigm

may position amylin agents as 1L therapy given tolerability and moderate

efficacy.

Novo's Ph 2 zenagamtide data in patients with T2D appeared competitive vs tirzepatide,

reaching numerically higher weightloss though modestly lower HbA1c reductions.

While the asset is still in the earlier stages of development, we increasingly see it as a

validated fast-follow-on entrant to CagriSema's.

Key Points

Ph 2 ZUPREME-1 petrelintide data does not appear to challenge Lilly's

demonstrated efficacy with eloralintide. Full data from Zealand's Ph 2 ZUPREME-1

trial of amylin analogue, petrelintide demonstrates a highly tolerable profile with rates